{"id":"W1968618374","doi":"10.1007/s10637-015-0230-x","title":"Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Pharmaceuticals International; Takeda Oncology","keywords":"Ixazomib; Medicine; Rash; Pharmacodynamics; Multiple myeloma; Pharmacokinetics; Adverse effect; Internal medicine; Proteasome inhibitor; Pharmacology; Gastroenterology; Oncology; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006906248,0.001035871,0.001080341,0.0002759263,0.0002422749,0.000605679,0.0005935215,0.0005540552,0.002225132],"category_scores_gemma":[0.0003643128,0.0002611325,0.0004508843,0.000320359,0.0004999352,0.0003955823,0.0002128636,0.001709348,0.0004590943],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00113405,"about_ca_system_score_gemma":0.001248814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00091489,"about_ca_topic_score_gemma":0.00417344,"domain_scores_codex":[0.9997978,0.00007770349,0.000008251155,0.00004185549,0.00003047972,0.00004395362],"domain_scores_gemma":[0.9997528,0.00003157216,0.00006885532,0.00001790052,0.00001606069,0.0001126841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2869432,0.07445688,0.01920584,0.001718105,0.001218933,0.001438541,0.000470439,0.008491459,0.3593593,0.0007203213,0.01048,0.235497],"study_design_scores_gemma":[0.2538178,0.5877266,0.04613974,0.0001394832,0.0007792871,0.002691907,0.00009270445,0.006116386,0.08730359,0.0004928845,0.01465145,0.00004811426],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920183,0.003799617,0.0007830721,0.0002645281,0.00005213399,0.000905192,0.0006015589,0.0001057246,0.001469806],"genre_scores_gemma":[0.9884901,0.003350371,0.002169772,0.0002939875,0.00007042812,0.0007505823,0.001741925,0.00002669532,0.003106052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002225132,"threshold_uncertainty_score":0.008228183,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07539078866375962,"score_gpt":0.3640018764683731,"score_spread":0.2886110878046134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}